

Jan Hoffmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3402863/publications.pdf>

Version: 2024-02-01

69
papers

3,546
citations

172457

29
h-index

138484

58
g-index

70
all docs

70
docs citations

70
times ranked

3298
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathophysiology of Migraine: A Disorder of Sensory Processing. <i>Physiological Reviews</i> , 2017, 97, 553-622.	28.8	1,168
2	Diagnosis, pathophysiology, and management of cluster headache. <i>Lancet Neurology</i> , The, 2018, 17, 75-83.	10.2	209
3	<i>In vivo</i> viscoelastic properties of the brain in normal pressure hydrocephalus. <i>NMR in Biomedicine</i> , 2011, 24, 385-392.	2.8	146
4	IL-1 β Stimulates COX-2 Dependent PGE2 Synthesis and CGRP Release in Rat Trigeminal Ganglia Cells. <i>PLoS ONE</i> , 2011, 6, e17360.	2.5	115
5	European Headache Federation guideline on idiopathic intracranial hypertension. <i>Journal of Headache and Pain</i> , 2018, 19, 93.	6.0	111
6	Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks. <i>JAMA Neurology</i> , 2018, 75, 1187.	9.0	106
7	Morphometric and volumetric MRI changes in idiopathic intracranial hypertension. <i>Cephalalgia</i> , 2013, 33, 1075-1084.	3.9	94
8	Glutamate and Its Receptors as Therapeutic Targets for Migraine. <i>Neurotherapeutics</i> , 2018, 15, 361-370.	4.4	93
9	Neurovascular mechanisms of migraine and cluster headache. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 573-594.	4.3	72
10	Evidence for orexinergic mechanisms in migraine. <i>Neurobiology of Disease</i> , 2015, 74, 137-143.	4.4	71
11	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. <i>Cephalalgia</i> , 2019, 39, 1475-1487.	3.9	69
12	Optic Nerve Head Quantification in Idiopathic Intracranial Hypertension by Spectral Domain OCT. <i>PLoS ONE</i> , 2012, 7, e36965.	2.5	68
13	Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. <i>Brain</i> , 2019, 142, 103-119.	7.6	62
14	Advances in the understanding of headache in idiopathic intracranial hypertension. <i>Current Opinion in Neurology</i> , 2019, 32, 92-98.	3.6	61
15	Migraine and Triggers: Post Hoc Ergo Propter Hoc?. <i>Current Pain and Headache Reports</i> , 2013, 17, 370.	2.9	58
16	Update on intracranial hypertension and hypotension. <i>Current Opinion in Neurology</i> , 2013, 26, 240-247.	3.6	53
17	New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. <i>Current Treatment Options in Neurology</i> , 2012, 14, 50-59.	1.8	52
18	Pearls and pitfalls in experimental <i>in vivo</i> models of migraine: Dural trigeminovascular nociception. <i>Cephalalgia</i> , 2013, 33, 577-592.	3.9	52

#	ARTICLE	IF	CITATIONS
19	Corticosteroids alter CGRP and melatonin release in cluster headache episodes. <i>Cephalalgia</i> , 2015, 35, 317-326.	3.9	51
20	Olfactory dysfunction in patients with idiopathic intracranial hypertension. <i>Neurology</i> , 2013, 81, 379-382.	1.1	47
21	Weather sensitivity in migraineurs. <i>Journal of Neurology</i> , 2011, 258, 596-602.	3.6	44
22	Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF. <i>Cephalalgia</i> , 2012, 32, 659-667.	3.9	44
23	Calcitonin gene-related peptide and disease activity in cluster headache. <i>Cephalalgia</i> , 2019, 39, 575-584.	3.9	44
24	Emerging Targets in Migraine. <i>CNS Drugs</i> , 2014, 28, 11-17.	5.9	43
25	Subjective Sleep Quality and Sleep Architecture in Patients With Migraine. <i>Neurology</i> , 2021, 97, e1620-e1631.	1.1	41
26	Neuroendocrine signaling modulates specific neural networks relevant to migraine. <i>Neurobiology of Disease</i> , 2017, 101, 16-26.	4.4	40
27	Efficacy and mechanism of anticonvulsant drugs in migraine. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 191-201.	3.1	39
28	PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?. <i>Pain</i> , 2020, 161, 1670-1681.	4.2	39
29	Structural Olfactory Nerve Changes in Patients Suffering from Idiopathic Intracranial Hypertension. <i>PLoS ONE</i> , 2012, 7, e35221.	2.5	33
30	Two TRPV1 receptor antagonists are effective in two different experimental models of migraine. <i>Journal of Headache and Pain</i> , 2015, 16, 57.	6.0	29
31	A systematic review of treatment for patients with burning mouth syndrome. <i>Cephalalgia</i> , 2022, 42, 128-161.	3.9	28
32	Brain structure and function related to headache: Brainstem structure and function in headache. <i>Cephalalgia</i> , 2019, 39, 1635-1660.	3.9	26
33	Methylprednisolone blocks interleukin 1 beta induced calcitonin gene related peptide release in trigeminal ganglia cells. <i>Journal of Headache and Pain</i> , 2016, 17, 19.	6.0	25
34	Peripheral provocation of cranial autonomic symptoms is not sufficient to trigger cluster headache attacks. <i>Cephalalgia</i> , 2018, 38, 1498-1502.	3.9	23
35	Diagnosis and treatment of idiopathic intracranial hypertension. <i>Cephalalgia</i> , 2021, 41, 472-478.	3.9	23
36	The influence of weather on migraine – are migraine attacks predictable?. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 22-28.	3.7	22

#	ARTICLE	IF	CITATIONS
37	Scientific advances in headache research: an update on neurostimulation. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 15-17.	2.8	20
38	The effect of CSF drain on the optic nerve in idiopathic intracranial hypertension. <i>Journal of Headache and Pain</i> , 2019, 20, 59.	6.0	18
39	Olvanil acts on transient receptor potential vanilloid channel 1 and cannabinoid receptors to modulate neuronal transmission in the trigeminovascular system. <i>Pain</i> , 2012, 153, 2226-2232.	4.2	17
40	Differential actions of indomethacin: clinical relevance in headache. <i>Pain</i> , 2021, 162, 591-599.	4.2	17
41	<i>N</i> -Methyl-D-aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats. <i>European Journal of Neuroscience</i> , 2019, 50, 2847-2859.	2.6	15
42	B-mode ultrasound assessment of pupillary function: Feasibility, reliability and normal values. <i>PLoS ONE</i> , 2017, 12, e0189016.	2.5	15
43	The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache. <i>Cephalalgia</i> , 2020, 40, 1474-1488.	3.9	14
44	Does <i>IIH</i> Alter Brain Microstructures? – A <i>DTI</i> -Based Approach. <i>Headache</i> , 2017, 57, 746-755.	3.9	12
45	Rapid improvement of olfaction after lumbar puncture in a patient with idiopathic intracranial hypertension. <i>Headache</i> , 2016, 56, 890-892.	3.9	10
46	Neuromodulation for the treatment of primary headache syndromes. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 261-268.	2.8	10
47	Primary cough headache treated with non-invasive vagal nerve stimulation. <i>Neurology</i> , 2020, 95, 593-594.	1.1	9
48	An Update on Imaging in Idiopathic Intracranial Hypertension. <i>Frontiers in Neurology</i> , 2020, 11, 453.	2.4	9
49	Greater occipital nerve block modulates nociceptive signals within the trigeminocervical complex. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1335-1340.	1.9	9
50	Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. <i>European Journal of Neurology</i> , 2022, 29, 2473-2480.	3.3	9
51	Facial pain beyond trigeminal neuralgia. <i>Current Opinion in Neurology</i> , 2021, 34, 373-377.	3.6	8
52	The utility of the lumbar puncture in idiopathic intracranial hypertension. <i>Cephalalgia</i> , 2019, 39, 171-172.	3.9	7
53	Impaired cerebrospinal fluid pressure. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 171-185.	1.8	5
54	Lumbar puncture rapidly improves olfaction in patients with idiopathic intracranial hypertension: A cohort study. <i>Cephalalgia</i> , 2020, 40, 429-436.	3.9	5

#	ARTICLE	IF	CITATIONS
55	Brain structure and function related to headache. <i>Cephalalgia</i> , 2019, 39, 1603-1605.	3.9	4
56	The analysis of calcitonin gene-related peptide â€“ a narrow path between useful and misleading findings. <i>Cephalalgia</i> , 2020, 40, 1271-1273.	3.9	4
57	S100B and NSE in Cluster Headache â€“ Evidence for Glial Cell Activation?. <i>Headache</i> , 2020, 60, 1569-1580.	3.9	4
58	CIDP-induced spinal canal obliteration presenting as lumbar spinal stenosis. <i>Neurology</i> , 2007, 68, 701-701.	1.1	3
59	Recent advances in headache research. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1379-1381.	2.8	3
60	Devices for Episodic Migraine: Past, Present, and Future. <i>Current Pain and Headache Reports</i> , 2022, 26, 259-265.	2.9	3
61	Hypoxic brain injury sparing the posterior circulation. <i>Neurology</i> , 2010, 74, 1476-1476.	1.1	2
62	Update on Pseudotumor Cerebri (Idiopathic Intracranial Hypertension). <i>Neurology International Open</i> , 2017, 01, E224-E231.	0.4	2
63	Headache Attributed to Intracranial Hypertension and Hypotension. <i>Headache</i> , 2016, , 189-205.	0.4	2
64	From basic mechanisms to therapeutic perspectives in cluster headache. <i>Current Opinion in Neurology</i> , 2022, 35, 336-342.	3.6	2
65	KCl-induced repetitive cortical spreading depression inhibiting trigeminal neuronal firing is mediated by 5-HT _{1B/1D} and opioid receptors. <i>Cephalalgia</i> , 2022, 42, 1339-1348.	3.9	2
66	Headache Highlights 2016: Junior Editorsâ€™ Choice. <i>Cephalalgia</i> , 2017, 37, 204-207.	3.9	1
67	Headache highlights 2017. <i>Cephalalgia Reports</i> , 2018, 1, 251581631877377.	0.7	0
68	Board Walk. <i>Cephalalgia</i> , 2022, 42, 88-89.	3.9	0
69	Clinical Significance and Therapeutic Management of Weight Loss in Patients With Idiopathic Intracranial Hypertension. <i>Neurology</i> , 2022, 99, 451-452.	1.1	0